Illumina said it will add 50,000 whole genomes paired with proteomic profiles to the Alliance for Genomic Discovery (AGD), with pharmaceutical partners GSK and Amgen leading the proteomics expansion. DeCode Genetics will produce the proteomic data using Illumina’s Protein Prep assay and SomaLogic technology. Regeneron Genetics Center will join the alliance, expanding the core dataset toward roughly 312,000 whole genomes. Illumina also highlighted longitudinal clinical data and EHR linkages already present in AGD’s holdings. Combining deep genomics with proteomics aims to improve causal inference for drug targets and mechanism‑of‑action studies; the move underscores big‑data integration as a front‑line strategy for target identification and translational R&D.